Lantern Pharma Inc.
LTRN · XNASCIK 1763950fmd_1G4B2EQ2HPHV8ME5BWPBZN3FDJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Jun 30, 2026, 30 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Research and development | – | 2 | 8 | 9 | 12 | 16 | 12 |
| Total operating expenses | 2 | 6 | 13 | 14 | 18 | 22 | 18 |
| Operating income | – | – | (13) | (14) | (18) | (22) | (18) |
| Other non-operating income (expense) | – | – | 0 | (0) | 1 | 1 | 0 |
| Income before taxes | – | – | – | – | – | – | 17 |
| Net income | (2) | (6) | (12) | (14) | (16) | (21) | (17) |
| Net income to common shareholders | – | (6) | (12) | – | – | – | – |